アスペルギルス症治療薬の世界市場2019-2023

◆英語タイトル:Global Aspergillosis Drugs Market 2019-2023
◆商品コード:IRTNTR30404
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月4日
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、アスペルギルス症治療薬の世界市場について調査・分析し、市場概要、市場環境、アスペルギルス症治療薬市場規模、製品別(トリアゾール、その他治療薬)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・アスペルギルス症治療薬の世界市場概要
・アスペルギルス症治療薬の世界市場環境
・アスペルギルス症治療薬の世界市場動向
・アスペルギルス症治療薬の世界市場規模
・アスペルギルス症治療薬の世界市場:業界構造分析
・アスペルギルス症治療薬の世界市場:製品別(トリアゾール、その他治療薬)
・アスペルギルス症治療薬の世界市場:地域別市場規模・分析
・アスペルギルス症治療薬の北米市場規模・予測
・アスペルギルス症治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・アスペルギルス症治療薬のアジア太平洋市場規模・予測
・アスペルギルス症治療薬の主要国分析
・アスペルギルス症治療薬の世界市場:意思決定フレームワーク
・アスペルギルス症治療薬の世界市場:成長要因、課題
・アスペルギルス症治療薬の世界市場:競争環境
・アスペルギルス症治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Astellas Pharma、Gilead、Johnson & Johnson Services、Merck Sharp & Dohme、Pfizerなどです。
【レポートの概要】

About this market
Strategic alliances to trend in the market. Pharmaceuticaq companies are working in collaboration for the development of medications for the treatment of aspergillosis. These alliances can enhance R&D activities for new drugs for the management of aspergillosis. Such alliances help companies to develop therapeutic drugs which can be introduced quickly into the market. Technavio’s analysts have predicted that the aspergillosis drugs market will register a CAGR of almost 4% by 2023.
Market Overview
Increasing awareness of aspergillosis
To create awareness about aspergillosis and other diseases and treatment options and avoid delay in diagnosis, the Aspergillus Website, funded by the Fungal Infection Trust in partnership with the University of Manchester, was created. The site provides detailed information about the fungus Aspergillus and the diseases it causes.
Increasing popularity of generic drugs
The development of generic drugs is simple, and less time taking and also requires minimal R&D expenditure than the innovator drugs. Thus, the launch of generic drugs in lesser price than the innovator drugs id diluting and hampering the growth of the aspergillosis drugs market.
For the detailed list of factors that will drive and challenge the growth of the aspergillosis drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Astellas Pharma and Gilead the competitive environment is quite intense. Factors such as the rising strategic alliances and the increasing awareness of aspergillosis, will provide considerable growth opportunities to aspergillosis drugs manufactures. Astellas Pharma, Gilead, Johnson & Johnson Services, Merck Sharp & Dohme, and Pfizer are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Triazoles – Market size and forecast 2018-2023
• Other therapeutics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
PART 10: VENDOR LANDSCAPE
• Market drivers
• Market challenges
PART 11: TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Astellas Pharma
• Gilead
• Johnson & Johnson Services
• Merck Sharp & Dohme
• Pfizer
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global infectious disease therapeutics market
Exhibit 03: Segments of global infectious disease therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Triazoles – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Triazoles – Year-over-year growth 2019-2023 (%)
Exhibit 22: Other therapeutics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other therapeutics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Astellas Pharma – Vendor overview
Exhibit 47: Astellas Pharma – Business segments
Exhibit 48: Astellas Pharma – Organizational developments
Exhibit 49: Astellas Pharma – Geographic focus
Exhibit 50: Astellas Pharma – Key offerings
Exhibit 51: Astellas Pharma – Key customers
Exhibit 52: Gilead – Vendor overview
Exhibit 53: Gilead – Business segments
Exhibit 54: Gilead – Organizational developments
Exhibit 55: Gilead – Geographic focus
Exhibit 56: Gilead – Key offerings
Exhibit 57: Gilead – Key customers
Exhibit 58: Johnson & Johnson Services – Vendor overview
Exhibit 59: Johnson & Johnson Services – Business segments
Exhibit 60: Johnson & Johnson Services – Organizational developments
Exhibit 61: Johnson & Johnson Services – Geographic focus
Exhibit 62: Johnson & Johnson Services – Segment focus
Exhibit 63: Johnson & Johnson Services – Key offerings
Exhibit 64: Johnson & Johnson Services – Key customers
Exhibit 65: Merck Sharp & Dohme – Vendor overview
Exhibit 66: Merck Sharp & Dohme – Business segments
Exhibit 67: Merck Sharp & Dohme – Organizational developments
Exhibit 68: Merck Sharp & Dohme – Geographic focus
Exhibit 69: Merck Sharp & Dohme – Segment focus
Exhibit 70: Merck Sharp & Dohme – Key offerings
Exhibit 71: Merck Sharp & Dohme – Key customers
Exhibit 72: Pfizer – Vendor overview
Exhibit 73: Pfizer – Business segments
Exhibit 74: Pfizer – Organizational developments
Exhibit 75: Pfizer – Geographic focus
Exhibit 76: Pfizer – Segment focus
Exhibit 77: Pfizer – Key offerings
Exhibit 78: Pfizer – Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: List of abbreviations



【掲載企業】

Astellas Pharma、Gilead、Johnson & Johnson Services、Merck Sharp & Dohme、Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アスペルギルス症治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆